Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs T3D 959 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PIONEER
  • Sponsors T3D Therapeutics

Most Recent Events

  • 25 Jul 2024 According to a T3D Therapeutics media release, company announced that CEO, John Didsbury, will be presenting new Phase 2 results in a modified intent-to-treat population of mild to moderate Alzheimer's patients at AAIC. The poster presentation will take place on Sunday, July 28th in Philadelphia, PA.
  • 03 Nov 2023 According to a T3D Therapeutics media release, topline results from this trial were presented at 16th international conference on Clinical Trials in Alzheimer's Disease (CTAD).
  • 03 Nov 2023 Results presented in the T3D Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top